Figure 2 | Scientific Reports

Figure 2

From: Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column

Figure 2

Effector function of the purified fractions. (a) Jurkat cell activation through engagement with immune-complex via FcγRIIIa (corresponds to ADCC) was evaluated by luciferase activity. (b) CDC was assessed by luciferase activity in the presence of human serum. (c) The binding level of antibody to the antigen-presenting cell was measured by flow cytometry using Alexa488-conjugated F(ab’)2 anti-human IgG-Fc.

Back to article page